OpenScience.ink

1 week ago • Antioxidants (Basel, Switzerland)

GLP-1’s role in controlling oxidative signals in metabolism and related diseasesGLP-1 as a Regulator of Oxidative Signalling in Metabolic Health and Disease.

🎖️ Top 10% JournalArticle

1 week ago • JAMA network open

Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Type 2 Diabetes: Updated Guidelines and Changes in Doctors' Knowledge Over TimePrescribing SGLTis and GLP-1 RAs for Patients With Type 2 Diabetes, Guideline Updates, and Longitudinal Knowledge Assessment Scores.

🥈 Top 2% JournalArticle

1 week ago • Life (Basel, Switzerland)

Fatty Liver Disease Linked to Metabolic Problems and Heart Risk: New Treatment Approaches Connecting Liver and Heart HealthMetabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis (MASLD/MASH) and Cardiovascular Risk: Emerging Therapeutic Strategies at the Interface of Liver and Cardiometabolic Disease.

📖 Top 30% JournalArticle

1 week ago • Journal of clinical medicine

Bile Duct and Pancreas Safety of Incretin-Based Treatments in Obesity and Type 2 Diabetes Compared Between Tirzepatide, Semaglutide, and DPP-4 InhibitorsBiliary and Pancreatic Safety of Incretin-Based Therapies in Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Comparison of Tirzepatide, Semaglutide, and DPP-4 Inhibitors.

📖 Top 20% JournalArticle

1 week ago • JAMA network open

Recording and Coding Body Mass Index in Medicare Patients Receiving Obesity TreatmentBody Mass Index Documentation and Coding Among Medicare Beneficiaries Undergoing Obesity Treatment.

🥈 Top 2% JournalArticle

1 week ago • Journal of clinical medicine

Semaglutide use in people with obesity and psoriasis over 18 months in real-life settingsSemaglutide in Patients with Obesity and Psoriasis: Insights from an 18-Month Real-World Experience.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Urinary Stone Return After Starting GLP-1 Therapy: A Romanian Study of Health, Kidney, and Hydration FactorsUrinary Stone Recurrence After Initiation of GLP-1-Based Therapy: A Romanian Retrospective Cohort Study of Clinical, Renal, and Hydration-Related Factors.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Effectiveness, side effects, and treatment adherence of Semaglutide and Liraglutide in Omani patientsReal-World Effectiveness, Documented Adverse Events, and Treatment Adherence of Semaglutide and Liraglutide in Omani Patients: A Retrospective Observational Study.

📖 Top 20% JournalArticle

1 week ago • International journal of molecular sciences

6-Gingerol boosts insulin release from insulin-producing cells without increasing gut hormone secretion6-Gingerol Potentiates β-Cell Insulin Secretion Without Acting as an L-Cell GLP-1 Secretagogue.

📖 Top 20% JournalArticle

1 week ago • International journal of molecular sciences

Clinical Outcomes of GLP-1 Receptor Agonist Treatment in Cancer PatientsGLP-1 Receptor Agonist Therapy in Patients with Cancer: A Review of Clinical Outcomes.

📖 Top 20% JournalSystematic Review

1 week ago • JAMA network open

Prescribing GLP-1 Receptor Agonists for People with Type 2 Diabetes and CancerGLP-1 RA Prescribing in Patients With Type 2 Diabetes and Cancer.

🥈 Top 2% JournalArticle

1 week ago • Metabolites

Weight gain after stopping GLP-1 and GIP/GLP-1 hormone treatments: A systematic reviewWeight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review.

📖 Top 20% JournalArticle

1 week ago • Pharmaceuticals (Basel, Switzerland)

Comparing how well people with type 2 diabetes stick to and keep taking SGLT-2 inhibitors versus GLP-1 receptor agonists, especially in those with heart diseaseSGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohort Study Comparing Adherence and Persistence with Specific Reference to Cardiovascular Disease.

📖 Top 20% JournalArticle

1 week ago • Pharmaceutics

Advances in How Anti-Obesity Drugs Work in the BodyProgress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective.

📖 Top 20% JournalArticle

1 week ago • Pharmaceutics

Retatrutide as a Single Drug Activating Three Hormone Receptors: Design, Development, and Review of New Phase 3 ResultsRetatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.

📖 Top 20% JournalArticle

1 week ago • Frontiers in endocrinology

Semaglutide's effectiveness for obesity varies between patients with and without food cravingsA retrospective real-world study on semaglutide effectiveness in patients with obesity: differences between patients with and without food craving.

🎖️ Top 10% JournalArticle

1 week ago • Genes

How Gene Activity Patterns Link Exenatide Treatment to Aging Signs in Immune Cells in Colorectal CancerSignature Definition Shapes Associations Between Exenatide-Related Transcriptional Programs and Macrophage Senescence Scores in Colorectal Cancer.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Body Weight and Metabolism Changes During Semaglutide and Tirzepatide Treatment in People from Türkiye Over TimeBody Weight Changes and Exploratory Metabolic Outcomes During Semaglutide and Tirzepatide Treatment: A Real-World Longitudinal Cohort Study from Türkiye.

📖 Top 20% JournalArticle

1 week ago • Nutrients

Changes in Bile Acid Processing and Nutrient-Triggered Hormone Responses After Two Types of Digestive Weight-Loss Surgery: RYGB Versus SADI-SChanges in Bile Acid Metabolism and Nutrient-Stimulated Hormone Responses After Malabsorptive Metabolic Surgery: RYGB Versus SADI-S.

🎖️ Top 10% JournalObservational Study

1 week ago • Journal of clinical medicine

Semaglutide and Similar Diabetes Drugs: Possible Links to Papillary Thyroid Cancer Risk and GrowthSemaglutide, Other GLP-1 Receptor Agonists, and Papillary Thyroid Carcinoma: A Narrative Review of Risk, Progression, and Mechanisms.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Weight Loss Amount, Fat Loss, and Muscle Loss Measured by Device During Obesity TreatmentWeight-Loss Magnitude, Fat Mass, and Device-Estimated Muscle Mass Loss During Obesity Pharmacotherapy.

📖 Top 20% JournalArticle

1 week ago • Frontiers in pharmacology

What people in Saudi Arabia know, think, and do about using GLP-1 receptor agonist medicinesKnowledge, attitudes, and practices among users of GLP-1 receptor agonists in Saudi Arabia: a cross-sectional study.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Using GLP-1 Treatments to Lower Heart Disease Risk in Kazakhstan: Evidence, Cost, Fair Access, and Practical IssuesGLP-1-Based Therapies for Cardiovascular Risk Reduction in Kazakhstan: Evidence, Affordability, Equity and Implementation Considerations.

📖 Top 20% JournalArticle

1 week ago • Nutrients

Effects of GLP-1 Receptor Drugs on Thinking Skills in Adults at Risk for Alzheimer's DiseaseImpact of GLP-1 Receptor Agonists on Cognitive Performance in Adults at Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

🎖️ Top 10% JournalSystematic Review

1 week ago • Chemical communications (Cambridge, England)

Changing GLP-1’s shape prevents its breakdown while keeping its metal-binding partStereochemical engineering of GLP-1 blocks proteolysis while preserving its metal-binding core.

📖 Top 20% JournalArticle

1 week ago • Neuropharmacology

Semaglutide lowers alcohol drinking and anxiety-like behavior during withdrawal in alcohol-preferring ratsThe GLP-1 receptor agonist semaglutide reduces alcohol consumption and anxiety-like behaviors during withdrawal in Marchigian Sardinian alcohol-preferring rats.

🎖️ Top 10% JournalArticle

1 week ago • Clinical and molecular hepatology

GLP-1 receptor drugs and health risks in people with type 2 diabetes and long-term viral liver infectionGLP-1 receptor agonists and adverse outcomes in patients with type 2 diabetes and chronic viral hepatitis.

🥈 Top 2% JournalArticle

1 week ago • Journal of the Endocrine Society

How well liraglutide works for children with type 2 diabetes in everyday lifeReal-world effectiveness of liraglutide in children with type 2 diabetes.

📖 Top 20% JournalArticle

1 week ago • Transplantation

Effects of Glucagon-like Peptide-1 Drugs in Heart Transplant Patients with Type 2 DiabetesGlucagon-like Peptide-1 Receptor Agonists in Heart Transplant Recipients With Type 2 Diabetes: A Multicenter Study.

Article

1 week ago • Current opinion in clinical nutrition and metabolic care

Glucagon-like peptide-1 drugs for treating obesity in older adults: possible risks and benefitsThe use of glucagon-like peptide-1 agonists as a treatment for obesity in older people: risks and benefits.

📖 Top 20% JournalArticle

← prevpage 4 of 16next →

Latest GLP-1 Therapies Research Papers